Skip to content
  • Global Key Solutions is now KeyPedia →
  • Independent Study of FDA Correspondence Finds Earliest CDER Warning Letter Citing AI Use →
  • KeyPedia Launches openFDA MCP Connector With an "Elsa for Industry" Approach →
  • KeyPedia Listed in TPRA’s TPRM Tools List →
  • Global Key Solutions is now KeyPedia →
  • Independent Study of FDA Correspondence Finds Earliest CDER Warning Letter Citing AI Use →
  • KeyPedia Launches openFDA MCP Connector With an "Elsa for Industry" Approach →
  • KeyPedia Listed in TPRA’s TPRM Tools List →
KeyPediaKeyPedia
  • Company
  • Platform
  • Media
  • KeyPedia Lite
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Aurobindo Pharma USA Inc
483•Aurobindo Pharma USA Inc•May 13, 2024

Aurobindo Pharma USA Inc – FDA 483, May 13, 2024

Record Details

The FDA inspected Aurobindo Pharma USA Inc."s corporate headquarters from May 13-15, 2024, uncovering critical non-compliance with the Drug Supply Chain Security Act (DSCSA). The primary issues observed included a systemic failure to implement robust procedures and systems for verifying product legitimacy and managing supply chain security. Specifically, the company"s written procedures were inadequate for identifying suspect products, conducting investigations with trading partners, validating transaction information, and ensuring timely notifications (within 24 hours) to the FDA regarding suspect, illegitimate, or high-risk products, as required by the DSCSA. Furthermore, Aurobindo Pharma lacked established systems to respond to notifications of illegitimate products from the FDA or trading partners, or to handle requests for product identifier verification. A significant violation involved the company"s failure to notify the FDA within 24 hours of a cargo theft on May 31, 2023, involving prescription drug products, which are considered illegitimate under the DSCSA. To achieve compliance, Aurobindo Pharma is required to develop and implement comprehensive systems and update their standard operating procedures to align with federal drug supply chain security regulations, ensuring proper investigation, notification, and response protocols.

Company
Aurobindo Pharma USA Inc
Inspection date
May 13, 2024
Product type
Drugs
Office
New Jersey District Office
Person
  • Samir C. Gala (Drug Investigator)

ID · 23d87088-0c57-415a-b47d-edecbaeb8f2b

Other documents for Aurobindo Pharma USA Inc

2
Document
Form 483 · June 15, 2024 
Form 483 · July 19, 2019 

With this document

Form 483 · May 13, 2024

Aurobindo Pharma USA Inc

  • The source document, to download any time
  • Yours for life in your Library
  • One-time purchase, no subscription. All sales final.

Comes with the profile

KRA (KeyPedia Risk Analysis)

How likely the FDA is to take enforcement action in the next 12 months.

Example18-month trend

Example5470Elevated90Higher18 months agoToday
The real score for Aurobindo Pharma USA Inc comes with its profile, not with a single document. How to get it

Form 483 · May 13, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Have an account? Sign in

Or discuss it with

What you get

  1. A document

    One file.

    • One FDA document, such as a Form 483
    • Yours for life in your Library
    • Each has its own price

    Your cart

    Your cart is empty.

    Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

    Browse documents
  2. The profile

    All the documents, plus intelligence about the company.

    • Every Aurobindo Pharma USA Inc document on file
    • The KRA score, which a single document does not include
    • Observations and inspection history
  3. Access

    This, for every company on KeyPedia.

    • Combine profiles in one search
    • Search across any modality: products, industry types, drugs, devices and recalls
    • Track everything as it changes
    • Other agencies too, such as EMA, Health Canada and UK MHRA
    here
KeyPedia
The intelligence layer for life sciences
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
Quick Links
HomePlatformUse CasesHardwarePricingResearchOur TechnologyFAQMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPrograms & Partnerships
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.